Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study

Mohammed A El-Bayoumi, Ahmed M El-Refaey, Alaa M Abdelkader, Mohamed M A El-Assmy, Angi A Alwakeel, Hanem M El-Tahan, Mohammed A El-Bayoumi, Ahmed M El-Refaey, Alaa M Abdelkader, Mohamed M A El-Assmy, Angi A Alwakeel, Hanem M El-Tahan

Abstract

Introduction: Respiratory failure is a life threatening complication of Guillain Barré syndrome (GBS). There is no consensus on the specific treatment for this subset of children with GBS.

Methods: This was a prospective randomized study to compare the outcome of intravenous immunoglobulin (IVIG) and plasma exchange (PE) treatment in children with GBS requiring mechanical ventilation. Forty-one children with GBS requiring endotracheal mechanical ventilation (MV) within 14 days from disease onset were included. The ages of the children ranged from 49 to 143 months.Randomly, 20 children received a five-day course of IVIG (0.4 g/kg/day) and 21 children received a five-day course of one volume PE daily. Lumbar puncture (LP) was performed in 36 patients (18 in each group).

Results: Both groups had comparable age (p = 0.764), weight (p = 0.764), duration of illness prior to MV (p = 0.854), preceding diarrhea (p = 0.751), cranial nerve involvement (p = 0.756), muscle power using Medical Research Council (MRC) sum score (p = 0.266) and cerebrospinal fluid (CSF) protein (p = 0.606).Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).

Conclusions: In children with GBS requiring MV, PE is superior to IVIG regarding the duration of MV but not PICU stay or the short term neurological outcome.The negative correlation between CSF protein values and duration of MV in PE group requires further evaluation of its clinical usefulness.

Trial registration: Clinicaltrials.gov Identifier NCT01306578.

References

    1. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70:1608–1613. doi: 10.1212/01.wnl.0000310983.38724.d4.
    1. Cheng Q, Jiang GX, Fredrikson S, Link H, de Pedro-Cuesta J. Incidence of Guillain-Barré syndrome in Sweden 1996. Eur J Neurol. 2000;7:11–16.
    1. Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:1146–1150.
    1. McLean M, Duclos P, Jacob P, Humphreys P. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology. 1994;5:443–448. doi: 10.1097/00001648-199407000-00011.
    1. Winner SJ, Evans JG. Age-specific incidence of Guillain-Barré syndrome in Oxfordshire. Q J Med. 1990;77:1297–1304.
    1. Hung KL, Wang HS, Liou WY, Mak SC, Chi CS, Shen EY, Lin MI, Wang PJ, Shen YZ, Chang KP. Guillain-Barré syndrome in children: a cooperative study in Taiwan. Brain Dev. 1994;16:204–208. doi: 10.1016/0387-7604(94)90070-1.
    1. Cheng Q, Wang DS, Jiang GX, Han H, Zhang Y, Wang WZ, Fredrikson S. Distinct pattern of age-specific incidence of Guillain-Barré syndrome in Harbin, China. J Neurol. 2002;249:25–32. doi: 10.1007/PL00007844.
    1. Allos BM. Association between Campylobacter infection and Guillain-Barré syndrome. J Infect Dis. 1997;176(Suppl 2):S125–S128.
    1. Allos BM. Campylobacter jejuni infection as a cause of the Guillain-Barré syndrome. Infect Dis Clin North Am. 1998;12:173–184. doi: 10.1016/S0891-5520(05)70416-5.
    1. Constant OC, Bentley CC, Denman AM, Lehane JR, Larson HE. The Guillain-Barré syndrome following Campylobacter enteritis with recovery after plasmapheresis. J Infect. 1983;6:89–91. doi: 10.1016/S0163-4453(83)95881-4.
    1. De Bont B, Matthews N, Abbott K, Davidson GP. Guillain-Barré syndrome associated with Campylobacter enteritis in a child. J Pediatr. 1986;109:660–662. doi: 10.1016/S0022-3476(86)80236-0.
    1. Grose C, Spigland I. Guillain-Barré syndrome following administration of live measles vaccine. Am J Med. 1976;60:441–443. doi: 10.1016/0002-9343(76)90762-2.
    1. Koturoglu G, Kurugol Z, Tekgul H, Ozcan T, Dizdarer C. Two cases of Guillain-Barré syndrome during measles elimination campaign in Izmir. Minerva Pediatr. 2008;60:1455–1457.
    1. Newton N Jr, Janati A. Guillain-Barré syndrome after vaccination with purified tetanus toxoid. South Med J. 1987;80:1053–1054. doi: 10.1097/00007611-198708000-00028.
    1. Cabrera J, Griffin DE, Johnson RT. Unusual features of the Guillain-Barré syndrome after rabies vaccine prepared in suckling mouse brain. J Neurol Sci. 1987;81:239–245. doi: 10.1016/0022-510X(87)90099-2.
    1. Kinnunen E, Farkkila M, Hovi T, Juntunen J, Weckstrom P. Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus vaccine campaign. Neurology. 1989;39:1034–1036.
    1. Ball R, Braun MM, Mootrey GT. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis. 2001;32:1273–1280. doi: 10.1086/319982.
    1. Bino S, Kakarriqi E, Xibinaku M, Ion-Nedelcu N, Bukli M, Emiroglu N, Uzicanin A. Measles-rubella mass immunization campaign in Albania, November 2000. J Infect Dis. 2003;187(Suppl 1):S223–S229.
    1. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barré syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine. 2007;25:5253–5255. doi: 10.1016/j.vaccine.2007.03.053.
    1. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–950. doi: 10.1016/S1474-4422(08)70215-1.
    1. van der Meche FG, van Doorn PA. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol. 1995;37(Suppl 1):S14–S31.
    1. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, Griffin JW, McKhann GM. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol. 1999;45:168–173. doi: 10.1002/1531-8249(199902)45:2<168::AID-ANA6>;2-6.
    1. Halawa EF, Ahmed D, Nada MA. Guillain-Barré syndrome as a prominent cause of childhood acute flaccid paralysis in post polio eradication era in Egypt. Eur J Paediatr Neurol. 2011;15:241–246. doi: 10.1016/j.ejpn.2010.11.008.
    1. Sladky JT. Guillain-Barré syndrome in children. J Child Neurol. 2004;19:191–200.
    1. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58:893–898. doi: 10.1001/archneur.58.6.893.
    1. Sharshar T, Chevret S, Bourdain F, Raphael JC. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003;31:278–283. doi: 10.1097/00003246-200301000-00044.
    1. Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJ, van Doorn PA, Steyerberg EW, Jacobs BC. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67:781–787.
    1. Durand MC, Lofaso F, Lefaucheur JP, Chevret S, Gajdos P, Raphael JC, Sharshar T. Electrophysiology to predict mechanical ventilation in Guillain-Barré syndrome. Eur J Neurol. 2003;10:39–44. doi: 10.1046/j.1468-1331.2003.00505.x.
    1. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology. 1985;35:1096–1104.
    1. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol. 1987;22:753–761.
    1. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326:1123–1129. doi: 10.1056/NEJM199204233261705.
    1. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–2257. doi: 10.1093/brain/awm004.
    1. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve. 1991;14:1103–1109. doi: 10.1002/mus.880141111.
    1. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2:750–753.
    1. Creange A, Belec L, Clair B, Degos JD, Raphael JC, Gherardi RK. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry. 1998;64:162–165. doi: 10.1136/jnnp.64.2.162.
    1. Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006;63:1066–1071. doi: 10.1001/archneur.63.8.1066.
    1. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3:36–44.
    1. Piepers S, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol WL. IVIG inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol. 2010;229:256–262. doi: 10.1016/j.jneuroim.2010.08.023.
    1. Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2011;82:87–91. doi: 10.1136/jnnp.2010.205856.
    1. Kaplan AA. A Practical Guide to Therapeutic Plasma Exchange. Malden: Blackwell Sciences; 1999.
    1. Lardone RD, Yuki N, Odaka M, Daniotti JL, Irazoqui FJ, Nores GA. Anti-GM1 IgG antibodies in Guillain-Barré syndrome: fine specificity is associated with disease severity. J Neurol Neurosurg Psychiatry. 2010;81:629–633. doi: 10.1136/jnnp.2009.183665.
    1. Wollinsky KH, Hulser PJ, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann KH, Rohrbach P, Schreiber H, Weber F, Kron M, Büchele G, Mehrkens HH, Ludolph AC, Rüdel R. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology. 2001;57:774–780.
    1. Gonzalez-Quevedo A, Carriera RF, O'Farrill ZL, Luis IS, Becquer RM, Luis Gonzalez RS. An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain Barré syndrome. Neurol India. 2009;57:288–294. doi: 10.4103/0028-3886.53282.
    1. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349:225–230.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe